Immunosuppression in Renal Transplantation
Induction therapy (basiliximab vs ATG vs alemtuzumab), maintenance triple therapy (tacrolimus + MMF + prednisone), TDM targets, CYP3A4 drug interactions, mTOR inhibitors, belatacept costimulation blockade, non-adherence as #1 cause of late graft loss, CNI nephrotoxicity, BK virus, CMV prophylaxis, PTLD, and malignancy risk.